Your Scleroderma Questions, Answered is a monthly Q&A column featuring responses from the SRF’s Chief Medical Officer, Dr. Gregory Gordon, who shares guidance grounded in decades of clinical expertise.
In this edition, he answers questions about the differences between CAR-T cell therapy and stem cell therapy, and why your doctor might suggest CAR-T therapy for your scleroderma treatment plan.
Question: What is the difference between stem cell therapy and CAR-T cell therapy?
Answer: Stem cell therapy and CAR-T cell therapy are both being used to try to reset an overactive immune system in scleroderma, but they work in different ways. With stem cell therapy, medications are used to essentially wipe out the patient’s existing immune system, then rebuild it using stem cells that were collected beforehand. Think of it as a full reset; the treatment clears out the immune cells causing the disease along with everything else, then starts fresh. This is a more established option, backed by several clinical trials, and is available today. It’s an intensive treatment with real risks, so it’s typically reserved for more severe cases.
CAR-T cell therapy takes a more targeted approach. Doctors remove some of the patient’s own T-cells (a type of immune cell) and re-engineer them in a lab to recognize and destroy a specific cell type that is believed to play a role in the tissue damage in scleroderma. The CAR-T cells are then re-infused into the patient, where they destroy those cells. This approach was originally developed for cancer treatment and is now being explored for autoimmune diseases, but it’s still experimental and only available through clinical trials.
In short, stem cell therapy fully clears and rebuilds the immune system, while CAR-T uses a more targeted cell therapy aimed at specific problem cells. Both are promising approaches for severe disease, but they differ in how established they are and how intense the overall process is.
Question: If my doctor mentions CAR-T cell therapy, does that mean my disease is progressing quickly?
Answer: No, not necessarily. There are several reasons your doctor might bring it up. First, it’s important to remember that CAR-T is still experimental. It is not FDA-approved for scleroderma and thus is only available through clinical trials. So if your doctor raises it, they may be gauging your interest in trial participation generally, separate from whether CAR-T specifically is the right treatment for you.
Second, your current treatment may not be working well enough. This could mean your disease isn’t responding well to your current medication, or it could mean that the current medications are working, but you’re experiencing side effects, and thus your doctor is considering CAR-T as an alternative to your current regimen.
Finally, it may just be general awareness. Your doctor may simply be flagging it as an option to know about, and potentially something to consider in the future, without implying anything about your current status.
Ask your doctor why they raised it, and whether they feel it’s something you should actively consider.
